Results 171 to 180 of about 19,152,238 (244)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them. [PDF]

Cancer Drug Resist
Pagano Mariano M, Sgarilli E, Mijnlieff D, Visuvasam B, Blesio A, Digiacomo G, Cavazzoni A, Ferracin M, Giovannetti E.   +8 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies. [PDF]

Pharmaceuticals (Basel)
Moussallem N, Awada A, El Darzi R, Tarhini A, Khaled A, Ashy C, Nasr W, El Masri A, Saad G, Itani M, Rizkallah J, Charbel N, Hatahet Z, Saade D, Abou Rahal J, Kreidieh F.   +15 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

SIK inhibitor HG-9-91-01 suppresses the pathogenic activity of fibroblast-like synoviocytes in rheumatoid arthritis. [PDF]

RMD Open
Wang X, Li Y, Li H, Mo L, Liu X, Qu Z, Wang J, Yan L.   +7 more
europepmc   +1 more source

Honokiol regulates Acute respiratory distress syndrome (ARDS)‐associated pulmonary fibrosis via the miR‐19a‐3p/POSTN axis

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Acute respiratory distress syndrome (ARDS) and subsequent pulmonary fibrosis are associated with high mortality and limited treatment options. Periostin (POSTN) is a profibrotic mediator predicted to be regulated by microRNA‐19a‐3p (miR‐19a‐3p), but the relevance of this axis in ARDS‐associated pulmonary fibrosis remains
Weilun Liu, Hsiaohsuan Wang, Hsuanfu Kuo, Chiahung Yen, Modasang Hua, Chiayuan Chang, Zhiwei Xu, Ifan Liu, Chongchao Hsieh, Chihhsin Hsu, Chiayang Li, Shuchi Wang, Yunghsiang Chen, Menghsuan Cheng, Polen Liu   +14 more
wiley   +1 more source

Managing capivasertib-induced hyperglycemia: a report of 3 cases. [PDF]

JCEM Case Rep
Cuan K, Oh SY, Milosavljevic J, Wong BY.
europepmc   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source